Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/25
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health MonthGlobeNewsWire • 05/01/25
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/25
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law FirmGlobeNewsWire • 04/10/25
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual MeetingGlobeNewsWire • 04/04/25
AXSM Stock Down on Top-Line Data From Depression Study on SolriamfetolZacks Investment Research • 04/02/25
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekInvestors Business Daily • 04/01/25
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?Zacks Investment Research • 03/14/25
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug FilingZacks Investment Research • 03/04/25
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used DrugsBenzinga • 02/24/25